Food allergy: Epicutaneous immunotherapy
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by Oceanside Publications Inc. in Journal of Food Allergy
- Vol. 2 (1) , 81-85
Abstract
The goal of allergen-specific immunotherapy for treatment of immunoglobulin E (IgE) mediated food allergy is to safely and effectively modify the allergic response, providing protection against anaphylaxis via ongoing exposure to the triggering allergen. Targeted allergen exposure via application of allergen to the epidermis has emerged as a potentially promising approach to desensitization. Epicutaneous immunotherapy (EPIT) uses allergen embedded on an adhesive patch secured to the skin. This allows for long-lasting allergen exposure, with subsequent antigen uptake and trafficking by skin antigen‐presenting cells to regional lymph nodes, which produce immunomodulatory effects in a manner that is noninvasive and limits exposure of allergen to the systemic circulation when applied to intact skin. As such, EPIT is overall well tolerated; local application site reactions are common, but systemic adverse effects are infrequent compared with other forms of immunotherapy. For peanut allergy, EPIT may increase the dose-triggering threshold in some individuals with peanut-allergy, especially younger children, but induction of remission has not been closely studied, and reliable predictors of clinical response are lacking. With U.S. Food and Drug Administration approved treatment for peanut allergy now available, the precepts of shared decision-making will be crucial in discussions with patients and their families with regard to treatment options.Keywords
This publication has 25 references indexed in Scilit:
- Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through ImmunotherapyThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adultsJournal of Allergy and Clinical Immunology, 2016
- Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanutCellular & Molecular Immunology, 2016
- Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patchJournal of Allergy and Clinical Immunology, 2016
- Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine modelJournal of Allergy and Clinical Immunology, 2015
- Food allergy: A practice parameter update—2014Journal of Allergy and Clinical Immunology, 2014
- The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long‐term protection from eosinophilic disorders in peanut‐sensitized miceClinical & Experimental Allergy, 2014
- Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in miceClinical and Translational Allergy, 2012
- Epicutaneous Immunotherapy Results in Rapid Allergen Uptake by Dendritic Cells through Intact Skin and Downregulates the Allergen-Specific Response in Sensitized MiceThe Journal of Immunology, 2011
- Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivityJournal of Allergy and Clinical Immunology, 2010